Acetylation of SERCA2a, Another Target for Heart Failure Treatment?
نویسندگان
چکیده
منابع مشابه
SERCA2a: a prime target for modulation of cardiac contractility during heart failure
Heart failure is one of the leading causes of sudden death in developed countries. While current therapies are mostly aimed at mitigating associated symptoms, novel therapies targeting the subcellular mechanisms underlying heart failure are emerging. Failing hearts are characterized by reduced contractile properties caused by impaired Ca(2+) cycling between the sarcoplasm and sarcoplasmic retic...
متن کاملSmall-molecule activation of SERCA2a SUMOylation for the treatment of heart failure
Decreased activity and expression of the cardiac sarcoplasmic reticulum calcium ATPase (SERCA2a), a critical pump regulating calcium cycling in cardiomyocyte, are hallmarks of heart failure. We have previously described a role for the small ubiquitin-like modifier type 1 (SUMO-1) as a regulator of SERCA2a and have shown that gene transfer of SUMO-1 in rodents and large animal models of heart fa...
متن کاملWeighing in on heart failure: the role of SERCA2a SUMOylation.
Heart failure is a complex clinical syndrome resulting from structural changes in the myocardium that affects the ability of the ventricle to fill with or eject blood.1 It affects at least 5 million patients in the United States and consumes over 6% of our health care budget.1 Nearly half a million new patients are diagnosed to have heart failure each year and the incidence of new cases are inc...
متن کاملHeterozygous disruption of SERCA2a is not associated with impairment of cardiac performance in humans: implications for SERCA2a as a therapeutic target in heart failure.
OBJECTIVE To verify whether a deficiency in the cardiac sarcoplasmic reticulum pump SERCA2a causes cardiac dysfunction in humans. DESIGN Cardiac performance was measured in a serendipitous human model of primary SERCA2a deficiency, Darier's disease, an autosomal dominant skin disorder caused by mutations inactivating one copy of the ATP2A2 gene, which encodes SERCA2a. METHODS Systolic and d...
متن کاملSERCA2a gene therapy for the prevention of sudden cardiac death: a future theranostic for heart failure?
Sudden cardiac death (SCD) is a common cause of mortality, with an annual incidence in the United States ranging from 180 000 to 450 000 cases annually.1 Given the frequency and gravity of SCD, there has been considerable effort directed toward decreasing the burden of SCD.2 Most of these efforts have focused on those at highest risk for SCD: (1) patients with heart failure (HF), specifically t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation Research
سال: 2019
ISSN: 0009-7330,1524-4571
DOI: 10.1161/circresaha.119.315017